file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%204th%20Lyophilisation%202010.txt
4th Lyophilisation Workshop Ensuring optimum formulations for pharmaceuticals and biologicals 7th - 9th September 2010, BSG Conference Centre, London, UK Key Speakers Filippo Orlandi, Sterile Manufacturing Manager, GlaxoSmithKline Otmane Bousif, Head, Formulation Development – Biotech Products, Sanofi -Aventis Richard Storey, Associate Principal Scientist, AstraZeneca Patrick Garidel, Head of Pharmaceutical Basic Development, Boehringer Ingelheim Pharma GmbH & Co. KG Joanne Broadhead, Team Manager, Liquids Manufacturing, AstraZeneca Miguel Galan, Innovation & R&D Director, Telstar Lyo Maik Guttzeit, Team Leader, Validation, GEA Lyophil Paul Matejtschuk, Principal Scientist, Standardisation Science, National Institute for Biological Standards and Control Kevin Ward, Director of Research and Development, BioPharma Technology Andrew Parker, Associate Director, Molecular Profiles Introduction 4th Lyophilisation Workshop With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today1, 2. Mirroring this trend, the market for lyophilising these compounds, currently approaching 200 million units3, is set to continue its year-on-year double digit growth. Without lyophilisation, 60% of biotherapeutics including recombinant proteins, plasma, vaccines and antibodies could not be commercially available3. Freeze-drying has become increasingly efficient in recent years, easier to use, more cost-effective and extremely accurate. It imparts higher stability, broader temperature tolerance, and longer shelf life to pharmaceutical formulations unstable in aqueous solution4.
file:///C|/Documents%20and%20Settings/user29/Desktop/Conference%20on%204th%20Lyophilisation%202010.txt (1 of 3)7/26/2010 3:00:40 PM